Traduction de «de-guidance » (Néerlandais → Français) :

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

Geneesk. 32, 1547-1550 (2001) National Institute for Clinical Excellence: NICE issues guidance on rosiglitazone for type 2 diabetes en NICE issues guidance on the use of pioglitazone for type 2 diabetes mellitus. [http ...]
Geneesk. 32, 1547-1550 (2001) National Institute for Clinical Excellence: NICE issues guidance on rosiglitazone for type 2 diabetes et NICE issues guidance on the use of pioglitazone for type 2 diabetes mellitus. [http ...]

Volgens de aanbevelingen van NICE [via [http ...]
D’après des recommandations émises par NICE [via [http ...]

03.05.2007: omzendbrief 490 + aanvraagformulier VHB + Guidance on the e-submission of renewal of a national Marketing Authorisation, aan de houders van een vergunning voor het in de handel brengen van geneesmiddelen voor humaan gebruik.
03.05.2007 : circulaire 490 + formulaire de demande AMM + Guidance on the e-submission of renewal of a national Marketing Authorisation, aux titulaires d’une autorisation de mise sur le marché de médicaments à usage humain.

Omzendbrief 490 (PDF, 1.71 MB) (+ addendum (PDF, 641.46 Kb) + VH formulier (DOC, 313 Kb) + guidance (PDF, 54.69 Kb)) van 03.05.2007 preciseerde in welke gevallen een aanvraag voor hernieuwing van een registratie of een VHB van een geneesmiddel wel of niet moest worden ingediend met ingang vanaf 01/01/2007, datum van inwerkingtreding van het voornoemde besluit van 14/12/2006 (deel 1 - deel 2
La circulaire 490 (PDF, 1.51 MB) du 03/05/2007 (+ addendum (PDF, 663.78 Kb) + formulaire demande RQ (DOC, 323 Kb) + guidance (PDF, 54.69 Kb)) précisait les cas dans lesquels une demande de renouvellement d’enregistrement ou d’AMM d’un médicament à usage humain devait ou non être introduite, à compter du 01/01/2007 date d’entrée en vigueur de l’arrêté du 14/12/2006 (partie 1 - partie 2 ) susvisé.

Op 22/02/2008 werd de 'Guidance for Industry on Providing Regulatory Information in Electronic format: Non-eCTD electronic Submissions (NeeS)' gepubliceerd op de EMEA website: [http ...]
Le document 'Guidance for Industry on Providing Regulatory Information in Electronic format: Non-eCTD electronic Submissions (NeeS)' a été publié sur le site de l’EMEA le 22/02/2008 : [http ...]

Professional Ethics Committee (with FPS Public Health - DG Guidance committee of the network of medical-
Professional Ethics Committee (with FPS Public Health - DG Guidance committee of the network of medical-

MANAGEMENT AND GUIDANCE BY THE CHIEF EXECUTIVE OFFICER’S SERVICES AND THE SUPPORT SERVICES 43
MANAGEMENT AND GUIDANCE BY THE CHIEF EXECUTIVE OFFICER’S SERVICES AND THE SUPPORT SERVICES 43

In verband met het nagaan van de bio-equivalentie zijn er regels vastgelegd; in de Europese Unie worden de regels vastgelegd door het Europees Geneesmiddelenbureau (European Medicines Agency of EMEA), gebruikt: Note for guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98 [http ...]
En ce qui concerne le contrôle de la bio-équivalence, des règles ont été fixées; dans l’Union européenne, on utilise les règles établies par l’Agence Européenne des Médicaments (European Medicines Agency ou EMEA): Note for guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98 [http ...]

MANAGEMENT AND GUIDANCE BY THE CHIEF EXECUTIVE OFFICER’S SERVICES AND THE SUPPORT SERVICES
MANAGEMENT AND GUIDANCE BY THE CHIEF EXECUTIVE OFFICER’S SERVICES AND THE SUPPORT SERVICES